Amgen Inc.

Michael R Degraffenreid

Xuelei Yan

Jay Patrick Powers

Daqing Sun

Dustin L McMinn

Yosup Rew

Xiao He

Lisa D Julian

Juan Carlos Jaen

Timothy David Cushing

Xiaolin Hao

Marc Labelle

Felix Gonzalez Lopez De Turiso

Mario G Cardozo

Marie-Louise Smith

Julio Cesar Medina

David John Kopecky

Youngsook Shin

Christopher Neil Farthing

Xian Yun Jiao

Sarah Elizabeth Lively

Andrew Smith

Simon A Burkitt

Sven P Rasmussen

Jonathan B Houze

Frank Kayser

Liusheng Zhu

Francisco Xavier Talamas

Ming Yu

Michael G Johnson

Xianghong Wang

Sharada Shenvi Labadie

Brian M Fox

Sean P Brown

Zhulun Wang

Michael D Bartberger

Alan C Cheng

Jason A Duquette

Hilary Plake Beck

Ana Zurisadai Gonzalez Buenrostro

Steven H Olson

Kexue Li

Yingcai Wang

Zhihong Li

David Louis Clark

Todd J Kohn

Mike Elias Lizarzaburu

Jacob A Kaizerman

Yunxiao Li

Marc Vimolratana

Jiasheng Fu

Manuel Zancanella

XianYun Jiao

Joshua Taygerly

Michael W Gribble, Jr

Jiang Zhu

Philip M Roveto

Craig Tomooka

Nigel P C Walker

David Karl Bedke

Adrian L Gill

The present invention provides MDM2 inhibitor compounds of Formula I, or the pharmaceutically acceptable salts thereof, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.

CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer

Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Compounds that inhibit MCL-1 protein

Benzamide derivatives of formula I are described and have therapeutic utility, particularly in the treatment of diabetes, obesity and related conditions and disorders: wherein R, R, R, R, R, R, R, R, and n are as defined herein.

Benzamide derivatives and uses related thereto

Benzamide derivatives of formulae I and II, and pharmaceutically acceptable salts, solvates, stereoisomers, and prodrugs thereof, and pharmaceutical compositions comprising the same, are described and have therapeutic utility, particularly in the treatment of diabetes, obesity, and related conditions and disorders: wherein R, R, R, R, R, R, R, R, R, R, R, and Rare defined as provided herein.

Arylsulfonamide compounds of formula I are described and have therapeutic utility, particularly in the treatment of diabetes, obesity and related conditions and disorders: 

Arylsulfonamides and uses related thereto

Compounds, compositions and methods that are useful in the treatment of inflammatory, immunoregulatory, metabolic, infectious and cell proliferative diseases or conditions are provided herein. In particular, the invention provides compounds which modulate the expression and/or function of proteins involved in inflammation, metabolism, infection and cell proliferation. The subject compounds contain a fused heterobicyclic ring.

Antiinflammation agents

Benzamide derivatives of formula I and II, and pharmaceutically acceptable salts, solvates, stereoisomers, and prodrugs thereof, and pharmaceutical compositions comprising the same, are described and have therapeutic utility, particularly in the treatment of diabetes, obesity, and related conditions and disorders: wherein R, R, R, R, R, R, R, R, R, R, R, and Rare defined as provided herein.

The present invention provides Aryl Sulfonamide Compounds having the formula: and prodrugs or pharmaceutically acceptable salts or prodrugs thereof. The Aryl Sulfonamide Compounds are useful for treating diabetes, obesity, and other diseases and disorders.

Aryl sulfonamide compounds and uses related thereto

Compounds, compositions and methods that are useful in the treatment of inflammatory, immunoregulatory, metabolic and cell proliferative conditions or diseases are provided herein. In particular, the invention provides compounds which modulate the expression and/or function of proteins involved in inflammation, metabolism and cell proliferation. The subject compounds contain quinoline or quinazoline rings.

Inflammation modulators

Growing community of inventors

San Francisco, CA, United States of America

Michael R Degraffenreid